Impact of Botulinum Toxin on Ocular Surface Parameters in Patients with Orbicularis Spasm: A Systematic Review and Meta-Analysis.

Authors

Davi Marçola Veiga, Alexandre Yamada Fujimura Júnior, Laura Goldfarb Cyrino, Daniela Coutinho da Silva, Karina de Oliveira Caneca, Dillan Cunha Amaral, Gustavo Rosa Gameiro, Ricardo Noguera Louzada

Published in

American journal of ophthalmology. Sep 16, 2026. Epub Sep 16, 2026.

Abstract

While botulinum toxin (BTX) is the primary treatment for facial dystonias and spasms, its effects on the ocular surface and corneal metrics are poorly defined and contradictory in current literature.
This systematic review and meta-analysis provides standardized evidence to support interpretation of BTX-related ocular surface outcomes in patients with blepharospasm and hemifacial spasm.
We searched PubMed, Embase, and Cochrane up to June 2025 using terms related to orbicularis spasm and ocular surface parameters. Eligible articles enrolled ≥7 patients with orbicularis spasm and reported pre and post-treatment outcomes. Primary endpoints included Schirmer I (ST1), tear break-up time (TBUT), ocular surface disease index (OSDI), Fluorescein Staining, and Astigmatism. A single-arm random-effects model in R was used to estimate mean differences.
Twenty-six studies (820 patients, 1,147 eyes) were included. OSDI scores significantly improved at 1-4 weeks (MD -11.77; 95% CI [-19.93, -0.28]; p < 0.001) and 3 months (MD -7.43; p < 0.0001). TBUT showed a significant increase at 3 months (MD 0.81; 95% CI [0.20, 1.43]; p < 0.01). ST1 and fluorescein staining remained stable across all intervals (p > 0.05), though meta-regression revealed that more injection sites correlated with higher ST1 at 1 month (R² = 80.3%; p < 0.001). Additionally, BTX was associated with a small but significant reduction in astigmatism (MD -0.14; p < 0.01).
BTX improves ocular surface symptoms and tear film stability in orbicularis oculi spasm, with neutral effects on Schirmer tests and reduced astigmatism. However, since these effects are likely influenced by the the reduction of involuntary eyelid contractions, these findings should not be interpreted as evidence of a direct biological effect of BTX on ocular surface physiology. Future studies incorporating objective ocular surface and spasm assessments are needed to clarify the underlying mechanisms.

PMID:
42749245
Bibliographic data and abstract were imported from PubMed on 17 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.